In a report published Wednesday, Sterne Agee analyst Greg T. Bolan resumed coverage on athenahealth ATHN with a Neutral rating and $84.00 price target.
In the report, Sterne Agee noted, “We think the keys to athenahealth's ability to maintain 30% core revenue growth will be: 1) mind share gain among physicians and 2) continued success with penetrating large physician practices, typically owned by or affiliated with for-profit health systems. Based on valuation and our belief that consensus CY13 sales growth estimates are too high, we re-initiate coverage with a Neutral rating and $84 price target.”
athenahealth closed on Tuesday at $87.92.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
